Catalog

9916.18 Direct Oral Anticoagulants: A Comprehensive History and Current Developments
Online
Added:

FREE FOR MEMBERS!
Course includes study material and exam.
Description: Direct Oral Anticoagulant (DOAC) medications are a relatively new class of antithrombotic agents prescribed to patients who have displayed adverse reactions to traditional anticoagulant therapy. Patients who have developed Heparin Induced Thrombocytopenia (HIT) antibodies due to prolonged heparin therapies have greatly benefitted from switching to DOAC’s for their antithrombotic regimens. However, DOAC’s utilize new mechanisms of clot prevention which have the ability to cause new abnormalities in routine coagulation assays that bench technologists must be able to identify during the daily process of assay analysis.
This presentation will provide a comprehensive history of the development of DOAC medications, tips for identifying patients taking DOAC’s while performing coagulation assays, as well as an outline of the current advances and new, experimental therapies under investigation in this emerging field.
Start date: Upon registration
Completion: Up to 52 weeks
Credits awarded per Session. See individual Sessions for further details.
Credits awarded
Type
Name
Sub type
Value
Certificate awarded

About this item

FREE FOR MEMBERS!

Course includes study material and exam.

Description: Direct Oral Anticoagulant (DOAC) medications are a relatively new class of antithrombotic agents prescribed to patients who have displayed adverse reactions to traditional anticoagulant therapy.  Patients who have developed Heparin Induced Thrombocytopenia (HIT) antibodies due to prolonged heparin therapies have greatly benefitted from switching to DOAC’s for their antithrombotic regimens.  However, DOAC’s utilize new mechanisms of clot prevention which have the ability to cause new abnormalities in routine coagulation assays that bench technologists must be able to identify during the daily process of assay analysis.

This presentation will provide a comprehensive history of the development of DOAC medications, tips for identifying patients taking DOAC’s while performing coagulation assays, as well as an outline of the current advances and new, experimental therapies under investigation in this emerging field.

Start date: Upon registration

Completion: Up to 52 weeks

 

Course/Activity Information

Learning Outcomes:

  • Provide background information about the classification and function of DOAC medications
  • Outline the various subtypes of DOAC medications listing their similarities and differences
  • List the brief histories and the most current advances in the field of DOAC medication development
  • Discuss the abnormalities in routine screening coagulation assays for patients taking DOAC medications
  • Describe the laboratory assays used to measure the level of DOAC medications in patient plasma samples

 

Speaker: Terrence Litavec, MLT

 

Terence Litavec has worked as a medical laboratory technologist since 2004 and has served as the MLT Director of the BCSLS. He currently works in the Hematology Department at LifeLabs in Burnaby.  Before that, he worked at Burnaby Hospital and Kelowna General Hospital, as well as Tacoma General Hospital and PhenoPath Laboratories, both in Washington State.  He is certified by both the CSMLS and the ASCP.  He is a certified specialist in hematology and coagulation, and he also has bench experience working in immunohistochemistry, flow cytometry, transfusion services, and some molecular methods such as FISH and PCR.  He has always had a passion for teaching, and he has written and presented numerous educational lectures throughout Canada.

 

Version Date: June 2018

 

PEP hours: 1.5

CPS credits: 0

*Note: PEP hours and/or CPS credits will only be awarded upon successful completion of Final Exam.

Close
Shopping Cart
Total:  Close

Loading Shopping Cart Items...